BPC-157 Research Guide: What Preclinical Studies Show

BPC-157 is one of the most-studied research peptides in tissue-repair research. Nearly all of that work is in animals and cell cultures. This guide covers what the compound is, what the published research has examined, and where the evidence stops.

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids. Its sequence is a partial sequence of a larger protein, “body protection compound,” first described in human gastric juice. That origin is why it is often called a gastric pentadecapeptide.

What has the research looked at?

Tendon, ligament and muscle models

Most published BPC-157 work comes from rodent injury models: transected Achilles tendons, ligament tears, muscle crush injuries and bone defects. A 2019 review in Cell and Tissue Research covered tendon, ligament and skeletal muscle studies. It reported consistently positive healing effects across those animal models. It also noted that the studies were small and that human data were missing [1].

What happens at the cell level

Cell-culture work has tried to explain those animal results. In a 2011 study in the Journal of Applied Physiology, tendon explants grew outward faster when BPC-157 was added. Rat tendon fibroblasts migrated and spread more and survived oxidative stress better. Cell proliferation itself did not change [2]. Researchers linked these effects to F-actin formation and to the FAK–paxillin signaling pathway.

A 2025 narrative review summarized the pathways reported so far. They include VEGFR2 signaling, nitric-oxide production through the Akt–eNOS axis, and ERK1/2 activation. All of these relate to angiogenesis (new blood-vessel growth) and fibroblast activity [3].

Gastrointestinal research

Given its gastric origin, BPC-157 has also been studied in models of gastrointestinal lesions, and in models where gut injury occurs together with other injuries. Seiwerth and colleagues review this work, and how it compares with standard angiogenic growth factors [4, 5].

Where the evidence stops

A 2025 systematic review in HSS Journal looked at BPC-157 from an orthopaedic sports-medicine angle. It confirmed that the evidence is overwhelmingly preclinical. It also noted that BPC-157 is not approved by the U.S. Food and Drug Administration [6]. A 2025 literature and patent review reached the same conclusion. It added that there are not enough clinical studies to approve the compound anywhere [7].

So the careful way to describe BPC-157 is as a research compound with an interesting set of animal and cell-culture results, not as an established therapy.

Laboratory handling

• Lyophilized peptides are generally stored cold, dry and protected from light. Follow the storage guidance on the product label and Certificate of Analysis.
• Check identity and purity against the batch COA before use. Ares Labs publishes a COA on each product page.
• Record lot numbers in your lab notebook so results can be traced to a specific batch.

FAQ

Is BPC-157 approved for human use?
No. BPC-157 is not FDA-approved for any use. Ares Labs sells it strictly for laboratory research.

Is BPC-157 the same as TB-500?
No. They are different peptides that are often studied side by side in tissue-repair models. See our TB-500 and thymosin beta-4 research guide.

How do I verify a batch?
Each Ares Labs product page shows a Certificate of Analysis with purity data for the current lot.

View BPC-157 research vials and the current COA →

References

1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PMID 30915550
2. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID 21030672
3. McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID 40789979
4. Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des. 2018. PMID 29998800
5. Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. PMID 34267654
6. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PMID 40756949
7. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals. 2025;18(2):185. PMID 40005999

For laboratory research use only. Not for human or animal consumption. This article summarizes published research for reference. It is not medical advice and makes no claim that any product treats, cures or prevents any condition.